Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 8/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | LOX | P28300 | 1/20 | 0.45 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.45 |
| ▸ | LOXL4 | Q96JB6 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27001761 | 0.99 | CES2 (0.53) | CES2ALDH1A1GFERLOXLOXL3 | |
| SCHEMBL6700291 | 0.79 | CES2 (0.63) | CES2ALDH1A1GFERLOXLOXL3 | |
| SCHEMBL5279293 | 0.78 | CES2 (0.65) | CES2ALDH1A1GFERLOXLOXL3 | |
| SCHEMBL6042079 | 0.76 | CES2 (0.67) | CES2ALDH1A1GFERLOXLOXL3 | |
| SCHEMBL4663174 | 0.76 | CES2 (0.67) | CES2ALDH1A1GFERLOXLOXL3 | |
| Bromide SCHEMBL27001757 | 0.74 | CES2 (0.54) | CES2ALDH1A1GFERLOXLOXL3 | |
| SCHEMBL419526 | 0.74 | CES2 (0.68) | CES2ALDH1A1GFERLOXLOXL3 | |
| Bromide SCHEMBL27001736 | 0.73 | CES2 (0.55) | CES2ALDH1A1GFERLOXLOXL3 | |
| SCHEMBL3438740 | 0.71 | CES2 (0.63) | CES2ALDH1A1GFERLOXLOXL3 | |
| SCHEMBL25454224 | 0.70 | CES2 (0.65) | CES2ALDH1A1GFERLOXLOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459900-B2 | Compounds for treating conditions related to oxidative stress | GIRI RAJAN SHOBHANATH (US) | 2025-11-04 | — | — | US | disclosed |
| US-20240262794-A1 | COMPOUNDS FOR TREATING CONDITIONS RELATED TO OXIDATIVE STRESS | GIRI RAJAN SHOBHANATH (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4304583-A1 | COMPOUNDS FOR TREATING CONDITIONS RELATED TO OXIDATIVE STRESS | Giri, Rajan, Shobhanath (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-116669704-A | Compounds for the treatment of oxidative stress related disorders | 拉詹·绍巴纳特·吉里 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022192477-A1 | COMPOUNDS FOR TREATING CONDITIONS RELATED TO OXIDATIVE STRESS | GIRI RAJAN SHOBHANATH (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459900-B2 | Compounds for treating conditions related to oxidative stress | CYP11B1, CYP11B2, NFE2L2 | CES2 2034/4885ALDH1A1 1300/4885GFER 419/4885 |
| US-20240262794-A1 | COMPOUNDS FOR TREATING CONDITIONS RELATED TO OXIDATIVE STRESS | CYP11B1, CYP11B2, NFE2L2 | CES2 2034/4885ALDH1A1 1300/4885GFER 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.